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Abstract Our case illustrates the difficulties involved in
diagnosing multicentric Castleman’s disease (MCD) in a
human immunodeficiency virus-infected man with febrile
episodes and malaise. In the absence of well-established
treatment protocols, we have chosen a new treatment
algorithm with rituximab, etoposide, and valganciclovir,
which led to the remission of clinical symptoms. Yet, we
advocate focused exploration for MCD in immunosup-
pressed patients with unclear febrile episodes, as recent
advances in treatment are promising.
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Introduction
In 1954, Benjamin Castleman first described a series of
cases which was regarded as a non-neoplastic polyclonal
lymphoproliferative disease or ‘pre-lymphoma’ [1]. Ini-
tially, it has been classified based upon clinical presenta-
tion (uni- vs. multicentric) and morphology (hyaline
vascular type vs. plasma cell type). In the setting of
immunosuppressed, particularly, human immunodeficiency
virus (HIV)-infected individuals, there is an increased
recognition of the human herpes virus 8 (HHV-8)-associ-
ated form with variable morphology, clinically presenting
as multicentric Castleman’s disease (MCD). Despite
mostly behaving as non-malignant disease, its influence on
morbidity and mortality is significant [2].
Case description
In February 2010, a 55-year-old homosexual man with HIV
infection was referred to our hospital with symptoms of
fever, weakness, and diarrhea. For the past 3 months, he
has been suffering from several febrile episodes lasting
2–5 days with spontaneous resolution. Extensive work-up
during previous hospitalizations failed to reveal a cause.
HIV has been diagnosed in 2007 and the patient was
treated with an antiretroviral regimen, including lopinavir/
ritonavir, lamivudine, and efavirenz. Despite excellent
virological response with undetectable plasma viral load
and several modifications in his antiretroviral medication,
the patient remained severely immunosuppressed with a
maximum of 107 CD4? T-lymphocytes/ll (5%).
On admission, our patient was in poor general condition,
febrile (39.5C) with a regular heart rate (74/min), hypo-
tensive (95/54 mmHg), and presented multiple, slightly
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enlarged cervical and inguinal lymph nodes and an enlarged
spleen. Laboratory tests showed pancytopenia (hemoglobin
of 7.4 g/dl, neutrophils 1.26 9 103/ll, platelets 103 9 103/
ll), an elevated C-reactive protein (CRP, 228 mg/l, normal
range \5 mg/l), and acute renal failure (creatinine
315 lmol/l). Several sets of blood cultures, examinations of
stool for bacteria, helminths, protozoas, and corresponding
serology remained negative. Mycobacterial infection was
excluded by repeated blood, respiratory, stool, and urine
samples. Upper and lower endoscopies were performed and
tissue biopsies showed no evidence of Tropheryma whipp-
lei, neoplasia, or inflammatory bowel disease. Bone marrow
aspiration and biopsy demonstrated non-specific changes
without dysplastic or myeloproliferative changes and
polymerase chain reaction (PCR) for leishmaniasis and
mycobacteriosis was negative. No evidence for hemo-
phagocytotic syndrome was found.
Thoraco-abdominal computed tomography (CT) con-
firmed splenomegaly (maximal longitudinal diameter
21 cm) and slightly enlarged iliac and hilar lymph nodes.
Fluorodeoxyglucose (FDG) positron emission tomography
scan revealed a pathological FDG uptake in axillary, cer-
vical and supraclavicular lymph nodes, spleen, and bone
marrow. Histological examination of a cervical lymph node
showed distorted secondary follicles with regressed ger-
minal centers, hyperplastic follicular dendritic cells, and a
significant surplus of interfollicular plasma cells.
Immunohistochemical staining was positive for HHV-8
latency-associated nuclear antigen (LANA) (Fig. 1). The
patient’s plasma HHV-8 viral load was 31,111 copies/ml.
The diagnosis of MCD could be made based on these findings.
Treatment with rituximab, etoposide, and valganciclovir
for six cycles according to the algorithm recently proposed
by Oksenhendler [2] was started. One year later, our patient
is still free from new episodes of fever and is working full-
time. Follow-up CT scan revealed a decreased size and
number of lymph nodes and spleen (longitudinal diameter
17 cm). Plasma HHV-8 viral load is no longer detectable.
Fig. 1 Lymph node histology
showing: a a lymph follicle with
a regressed germinal center and
radially penetrating blood
vessels (right), accompanied by
an increased interfollicular
plasma cell content (asterisk);
b double-staining for the light
chains kappa (brown) and
lambda (blue) highlights the
massive increase of polytypic
plasma cells; c nuclear staining
for the latency-associated
nuclear antigen (LANA-1) in a
few plasmablasts within the
follicular mantle zone
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Discussion
Disease presentation in MCD varies widely and is non-
specific. The most common signs and symptoms include
malaise, fever, night sweats, weight loss, generalized
lymphadenopathy, splenomegaly, edema, and cytopenia [3,
4]. Untreated MCD exhibits a progressive clinical course
which may result in malignancy and death. To confirm the
diagnosis, the detection of HHV-8-infected cells using
immunohistochemical techniques in lymph nodes or bone
marrow is required. Levels of HHV-8 replication in plasma
reflect disease activity and may be useful as a follow-up
parameter. Yet, this test is reserved for specialized labo-
ratories, whereas CRP is widely available and serves, while
non-specific, as a good surrogate marker for disease
activity together with the clinical follow-up [5].
Epidemiologic data demonstrate a highly increased
incidence of MCD in HIV-infected individuals compared
to immunocompetent persons. Improvement of the immu-
nologic response and treatment of the underlying disease is
crucial, irrespective of the cause of immunosuppression.
However, there is no firm evidence of a close correlation
between the CD4? T-lymphocytes cell count or the use of
antiretroviral therapy and the resolution of MCD. Inter-
estingly, in a study by Powles et al. [6], the calculated
incidence retrieved from the Chelsea and Westminster HIV
Cohort showed an increase of MCD in the era of highly
active antiretroviral therapy, while other HIV-related dis-
eases, such as Kaposi’s sarcoma, became less frequent. It is
not clear whether this is a reporting bias due to a higher
number of biopsies or a real increase of MCD in the
population of HIV-infected individuals.
Due to the association of active HHV-8 replication with
MCD, antiviral agents such as ganciclovir/valganciclovir
have been successfully used [7]. Another promising
approach for treatment in selected cases is rituximab, a
chimeric monoclonal antibody against CD20 protein on
HHV-8-infected CD20-presenting cells. Several trials have
demonstrated a partial to complete remission and sup-
pression of HHV-8 replication after a 3-month course of
treatment with rituximab [8]. Very recent data show that
the introduction of rituximab-based therapy has improved
the outcome dramatically [9]. Antineoplastic agents such as
etoposide or vinblastine have been demonstrated to be
highly active in preventing the evolution of MCD towards
lymphoma [10]. However, the long-term administration of
these agents is limited by possible oncogenic effects.
Because of the unspecific findings, MCD can be difficult
to diagnose in the setting of episodic fever and malaise.
The optimal treatment regime for MCD is not yet estab-
lished and standard therapy protocols do not exist.
Untreated, it leads to significant morbidity and death. We
advocate exploring for MCD in unclear febrile episodes, as
recent advances in treatment appear promising.
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